AIM-001 treats solid tumors. Activity is independent of tumor type, biomarker and mutational status.
AIM-001 helps the immune system target and attack tumors. Makes invisible tumors visible.
AIM-001 activates and recruits the largest T cell pool to the tumor by triggering transplant rejection.
AIM-001 was designed to maximize efficacy of checkpoint immunotherapy.
Improve outcomes for patients with advanced solid tumors and limited therapeutic options. A minority of patients have had remarkable responses, however the majority do not experience clinically meaningful responses.
Tumors hide from the immune system and exclude immune cells. Only immune cell rich tumors respond to checkpoint immunotherapy. AIM-001 induces immune cells to flood the tumor.
AIM-001 is an intratumoral therapy that converts “cold” tumors “hot” by activating and recruiting the largest T cell pool in human biology to the tumor to increase durable response rates and patient eligibility.
Clinically safe and active TLR agonism + genetically mismatched adipocytes trigger an influx of activated immune cells to convert checkpoint refractory into checkpoint responsive disease.
